# Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)

> **NCT02044601** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Onartuzumab
- **DRUG:** Erlotinib
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT02044601
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-06
- **Primary completion:** 2019-06
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2014-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02044601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02044601, "Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02044601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*